Form 4: Humacyte Officer Shamik J. Parikh Reports Acquisition of 7,500 Shares

Humacyte's Chief Medical Officer, Shamik J. Parikh, reports purchasing 7,500 shares of common stock at $1.55 per share on April 10, 2025.

Summary

• On April 10, 2025, Shamik J. Parikh, Chief Medical Officer of Humacyte, Inc., acquired 7,500 shares of common stock.
• The purchase price was $1.55 per share.
• Following the transaction, Parikh directly owns 7,500 shares of Humacyte common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of an insider stock purchase. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. It provides transparency into the transactions of those with access to non-public information.

Stakeholder Impact

• The purchase of shares by a company officer can sometimes be viewed positively by shareholders, as it may indicate confidence in the company's future performance.

Key Dates

Keywords

Form 4, Humacyte, HUMA, Insider Trading, Shamik J. Parikh, Chief Medical Officer, Stock Acquisition, Beneficial Ownership